Rybelsus 14 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FP7P8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,415
Award facts
- Contract value 100% obligated
- $16,414.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,414.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Rybelsus 14 mg tablets (30-count units) on August 6, 2025, with completion targeted for August 7, 2025. This non-set-aside award represents a routine pharmaceutical procurement for military healthcare support, with performance based at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with DLA Troop Support Medical, valued at $999.9 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant position within the Defense Logistics Agency's medical supply chain as a critical vendor for federal military and veteran healthcare systems. The company consistently demonstrates capability to meet federal procurement requirements through competitive awards across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. This particular award for Rybelsus—a diabetes management medication—exemplifies the routine operational deliveries executed under the broader SPE2DX prime contract, which provides DLA and affiliated agencies including the Defense Health Agency and U.S. Coast Guard with flexible access to comprehensive pharmaceutical commodities.
Quick answers
Who was awarded contract SPE2DB25FP7P8?
SPE2DB25FP7P8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FP7P8 worth?
The government has obligated $16,415 on SPE2DB25FP7P8.
Is contract SPE2DB25FP7P8 an order under another contract?
Yes. SPE2DB25FP7P8 is a delivery order under SPE2DB20D3103, an indefinite delivery contract.
Was contract SPE2DB25FP7P8 competed?
The extent of competition for SPE2DB25FP7P8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award